Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
February 28 2023 - 7:30AM
Syneos Health® (Nasdaq: SYNH), a leading fully integrated
biopharmaceutical solutions organization, today announced the
launch of a Decentralized Clinical Trial (DCT) Site Network to
drive appropriate DCT adoption and enable high quality delivery of
DCTs and digital health technology solutions. The introduction of
the Syneos Health DCT Site Network complements the Company’s
existing Site Advocacy Group, continuing the momentum for
decentralized solutions to bring clinical trials closer to the
patient.
The novel DCT Site Network was created by leveraging Syneos
Health’s global connections of Catalyst Sites, Networks and
experienced Principal Investigators. First launching in the US and
Canada, the DCT Site Network will cover various therapeutic areas
such as Internal and General Medicine, Family Practice, Neurology,
Endocrinology, Pediatrics, Psychiatry, Dermatology, Cardiology,
Obstetrics and Gynecology, Ophthalmology, and Respiratory. Over
time, Syneos Health will expand the network to include numerous
sites across Europe and APAC.
“Obtaining site buy-in for delivering decentralized solutions is
often the biggest hurdle to driving DCT adoption. Through our DCT
Site Network, we have been able to tackle this challenge and work
with crucial site partners to make significant headway in this
emerging and essential arena,” said Noolie Gregory, VP, DCT
Operations, Syneos Health. “The DCT Site Network will allow for
faster triage of sites to be considered for DCT studies, creating
efficiencies in site adoption, training, and allowing for more
successful implementation across the board. We’re excited to
harness the power of this network and realize meaningful momentum
for our customers and industry partners as the demand for DCTs and
digital health technology solutions continues to increase.”
Decentralized Solutions from Syneos Health combine deep
insights, agile technologies, innovative trial design experience
and operational excellence to transform clinical development. The
Company’s unique DCT capabilities integrate the “voice of the site
and patient” into clinical trials to address significant challenges
in certain therapy areas, maximizing behavioral understanding to
improve patient participation. As DCTs allow for the collection of
more real-time data and real-world insights, these efforts also
critically support and influence successful commercialization
strategies.
The launch of the Syneos Health DCT Site Network continues the
Company’s investment in advancing differentiating technology and
data solutions.
To learn more about Decentralized Solutions from Syneos Health,
visit
https://www.syneoshealth.com/solutions/clinical-development/decentralized-solutions.
About Syneos HealthSyneos Health® (Nasdaq:SYNH)
is a leading fully integrated biopharmaceutical solutions
organization built to accelerate customer success. We translate
unique clinical, medical affairs and commercial insights into
outcomes to address modern market realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics. Together
we share insights, use the latest technologies and apply advanced
business practices to speed our customers’ delivery of important
therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance
from lab to life®, visit syneoshealth.com or subscribe to
our podcast.
Investor Relations Contact: |
Press/Media Contact: |
Ronnie Speight |
Gary Gatyas |
Senior Vice President, Investor Relations |
Executive Director, External Communications |
+1 919 745 2745 |
+1 908 763 3428 |
Investor.Relations@syneoshealth.com |
gary.gatyas@syneoshealth.com |
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024